New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format ...

Pharma needs to utilise the latest technology to maintain agility, and hence competitiveness, across the supply chain, says Patrick Lemoine. The pharmaceutical industry has been one of the best ...

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline. Despite more treatment options being a positive, Ben ...

Learn how prioritising sustainability efforts can lead to long-term growth in drug manufacturing, focusing on gene therapy and GLP-1. Discover the benefits and strategies for sustainable practices ...

Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

BioNTech chalks up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine in a phase 2 trial in melanoma.

Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK. The AIM-listed company said this morning that the ...

People who trust pharma are more interested in using the industry’s services – making building confidence in the sector key to realising the potential of patient centricity. Just 13% of people ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and peripheral artery disease (PAD), potentially adding yet another ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company.